0.98
-0.038(-3.73%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.05 |
| Day High | 1.07 |
| Day Low | 0.97 |
| 52-Week High | 3.48 |
| 52-Week Low | 0.83 |
| Volume | 2.07M |
| Average Volume | 884,943 |
| Market Cap | 70.89M |
| PE | -0.47 |
| EPS | -2.1 |
| Moving Average 50 Days | 1.33 |
| Moving Average 200 Days | 1.61 |
| Change | -0.04 |
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent DirectorsBURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused o
Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
GlobeNewswire Inc.
Aug 07, 2025 8:05 PM GMT
Offering included participation from leading institutional investors, including Nantahala Capital, ADAR1 Capital Management, Second Line Capital, 683 Capital, and SilverArc Capital Proceeds expected to extend cash runway through key upcoming 3-and 6-
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
GlobeNewswire Inc.
Aug 06, 2025 8:05 PM GMT
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2